Search
for
Sort by
Research 30 of 1000+
- Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
- Cutaneous Side Effects in Non-Small Cell Lung Cancer Patients Treated with Iressa (ZD1839), an Inhibitor of Epidermal Growth Factor
- Poly(rC) binding protein 2 acts as a negative regulator of IRES-mediated translation of Hr mRNA
- A Case of Hair Change and Acneiform Eruption Induced by ZD1839 (Iressa$^{(R)}$)
- Shifting IRES versus Cap-initiated translation during homeostatic stem cell differentiation and stress
- Oral Combination Treatment of Gefitinib (IressaTM) and Sasam-Kyeongokgo: Synergistic Effects on the NCI-H520 Tumor Cell Line
- Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study
- Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance
- Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
- Epidermal Deletion of Rac1 Causes Stem Cell Depletion, Irrespective of whether Deletion Occurs during Embryogenesis or Adulthood
- Is obesity surpassing the conventional risk factors in the development of CAD, irrespective of age?
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- Revisión sistemática de los efectos adversos cutáneos causados por fármacos inhibidores de los puntos de control inmunitario: características, manejo y pronóstico
- [Translated article] Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
- Potassium Channel Openers Increase Aortic Elastic Fiber Formation and Reverse the Genetically Determined Elastin Deficit in the BN Rat
- The only way is ethics? Applying for National Health Service ethical approval and governance for research with children
- Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
- Differentiation stage-specific use of cap-independent and cap-dependent translation initiation in hematopoiesis
- IMMUNE-RELATED SKIN TOXICITIES TO CHECKPOINT INHIBITORS THERAPY
- 0163 Specific targeting of dermal papilla cells with Hhip-Cre
- MmuPV1-Induced Cutaneous Squamous Cell Carcinoma Arises Preferentially from Lgr5+ Epithelial Progenitor Cells
- BH15 The burden of alopecia areata: examining baseline health-related quality of life and clinical assessment tools
- Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment
- Personality Disorders and Psychopathologic Symptoms in Patients With Androgenetic Alopecia
- HPA axis stress reactivity and hair cortisol concentrations in recently detoxified alcoholics and healthy controls with and without childhood maltreatment
- Evaluation of Galectin-3 level in Male Androgenetic Alopecia Patients
- FREQUENCY OF SKIN MANIFESTATIONS IN PATIENTS ON CHEMOTHERAPY